A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Copanlisib (Primary) ; Rogaratinib (Primary)
- Indications Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCOCO
- Sponsors Bayer
- 03 Aug 2018 Planned End Date changed from 21 Apr 2021 to 10 Mar 2021.
- 03 Aug 2018 Planned primary completion date changed from 21 Apr 2021 to 10 Mar 2021.
- 01 Aug 2018 Status changed from not yet recruiting to recruiting.